BioCentury
ARTICLE | Company News

NEOT, BMY cancer deal

November 5, 2001 8:00 AM UTC

Neotherapeutics (NEOT) subsidiary NeoOncoRx received worldwide rights to develop and market elsamitrucin from Bristol-Myers Squibb (BMY). NeoOncoRx plans to begin a U.S. Phase II trial of elsamitrucin...